Astaxanthin is a red-orange ketocarotenoid produced primarily by the microalgae Haematococcus pluvialis. Unlike most antioxidants, it inserts perpendicularly across cell membranes, spanning both the lipid-soluble interior and the water-soluble surface simultaneously. That structural positioning gives it an unusually broad reach: it can quench free radicals and singlet oxygen in compartments where other antioxidants cannot operate. Oxidative stress and chronic low-grade inflammation are now understood to be central drivers of arterial disease, which is why astaxanthin has drawn interest from cardiovascular researchers.
The evidence base spans animal models, small human randomized controlled trials, and several meta-analyses. Findings on lipid profiles are mixed, with one meta-analysis finding no significant effect and another finding small changes with high heterogeneity, and human data on inflammatory markers are limited. Large, long-term trials in people with established cardiovascular disease are also lacking [12][15][20]. This article summarizes what the current research supports, where genuine gaps exist, and what distinguishes astaxanthin mechanistically from more familiar antioxidant supplements.
Key Takeaways
- Astaxanthin spans both the lipid and aqueous phases of cell membranes, giving it an unusually broad antioxidant reach that may help protect LDL from oxidative modification: a key early step in atherosclerosis [1].
- A human randomized controlled trial found natural astaxanthin increased HDL-cholesterol and adiponectin in adults with mild hyperlipidemia [2]; a 2025 meta-analysis reviewed its effects on lipid profile parameters across multiple trials [3].
- Animal studies show astaxanthin may reduce PCSK9 expression (increasing LDL receptor availability), decrease lipid peroxidation, and support endothelial function, but these mechanisms await confirmation in large human trials.
- Blood pressure is a separate question from lipids: a 2020 meta-analysis of 14 randomized trials found no association between astaxanthin and systolic or diastolic pressure [11].
- Astaxanthin has no established cardiovascular benefit in people. If it is used at all, it belongs alongside diet, exercise, and appropriate medical care rather than as a standalone intervention [12][21][22].
- Most human trials are small and short-term; large randomized controlled trials in people with established cardiovascular disease are still lacking, and caution is warranted when interpreting current findings.
How Astaxanthin May Protect the Heart: The Mechanism
Cardiovascular disease involves a cascade of interconnected events: LDL cholesterol becoming oxidized in arterial walls, inflammatory signaling accelerating plaque formation, and blood vessel function deteriorating over time. Astaxanthin may intervene at several of these steps. Its perpendicularly anchored position within the phospholipid bilayer allows it to protect both membrane leaflets simultaneously, enabling it to neutralize lipid-soluble radicals inside the membrane and water-soluble radicals at its surface: a dual-phase action considered structurally distinct from carotenoids that reside only in the lipid core [1].
Beyond direct radical scavenging, astaxanthin appears to suppress nuclear factor-kappa B (NF-κB), a master regulator of inflammatory gene expression that plays a central role in atherosclerosis [4]. It also influences lipid metabolism at the molecular level: a 2026 animal study found that astaxanthin reduced expression of PCSK9, a protein that degrades LDL receptors, while simultaneously upregulating LDL receptor density on cell surfaces, a dual mechanism that could meaningfully lower circulating LDL [5]. These are promising mechanistic pathways, though most of this level of evidence originates from animal or cell culture research and has not yet been confirmed in large human trials.
LDL Oxidation and Atherosclerosis Risk: What Animal Models Show
Oxidized LDL is considerably more atherogenic than native LDL. Once oxidized, LDL particles are taken up by macrophages in arterial walls, forming foam cells: the cellular hallmark of early atherosclerotic plaques. Astaxanthin’s lipid-phase antioxidant activity makes it a direct candidate for interrupting this process. In rats fed a high-fat diet, astaxanthin combined with flaxseed oil significantly attenuated markers associated with atherosclerosis risk, including measures of lipid peroxidation [6].
Research note: In volunteers given 1.8, 3.6, 14.4 or 21.6 mg astaxanthin daily for 14 days, the delay before their LDL oxidised lengthened by 5.0, 26.2, 42.3 and 30.7% respectively, while a control group showed no change. This is a blood-marker result, not a clinical outcome [27].
A 2026 study using an ovariectomized rat model, commonly used to study post-menopausal cardiovascular risk, found that astaxanthin supplementation, particularly when combined with selenium, reduced lipid peroxidation biomarkers and improved the overall cardiovascular marker profile [5]. This suggests the antioxidant benefit may be relevant in hormonal contexts where cardiovascular risk rises. Rodent lipid biology and LDL metabolism differ meaningfully from human physiology, however, and these findings should not be interpreted as confirmed human outcomes.
Lipid Profile Effects in Human Studies
The most directly relevant human data on astaxanthin and lipids comes from a randomized controlled trial in adults with mild hyperlipidemia. Participants receiving natural astaxanthin showed significant increases in serum HDL-cholesterol, the protective lipoprotein, as well as increased adiponectin, a hormone associated with improved insulin sensitivity and lower cardiovascular risk [2]. In that 12-week trial of 61 non-obese subjects given 0, 6, 12 or 18 mg/day, LDL-cholesterol was unaffected at every dose, triglycerides fell significantly at 12 and 18 mg/day, and HDL-cholesterol rose significantly at 6 and 12 mg/day [2]. Whether the HDL signal holds up when trials are pooled is less clear, as the pooled analyses discussed below show [11][12].
Two lipid meta-analyses disagree: one found no effect, the other small favorable changes
No significant effect
280 participants in 7 RCTs. LDL cholesterol changed by +1.25 mg/dl (95% CI -6.70 to +9.21) and triglycerides by -4.76 mg/dl (95% CI -21.52 to +12.00).
Small favorable changes
Adults in 9 astaxanthin RCTs. LDL-C -0.11 mmol/L (-0.21 to -0.01), HDL-C +0.13 (0.05 to 0.21), total cholesterol -0.22 (-0.32 to -0.12), triglycerides -0.46 mmol/L (-0.83 to -0.10).
High heterogeneity
The second review's authors say included trials varied in number, sample size and duration, and some RCTs were low quality, so the findings carry uncertainty.
Whether astaxanthin changes blood lipids depends on which pooled analysis you read, so treat the effect as unsettled.
Cards show each analysis as reported; the numbers are not directly comparable across cards. Source: Ursoniu et al., Archives of Medical Science 2015; Wan et al., Nutrients 2024.
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
A 2025 systematic review and meta-analysis specifically examined astaxanthin supplementation at moderate to high doses across multiple randomized controlled trials and reported on its effects on lipid profile parameters including LDL, HDL, and triglycerides [3]. Meta-analyses provide the most comprehensive current picture, though astaxanthin trials tend to be small and heterogeneous. A broader meta-analysis of nutraceutical combinations that included astaxanthin also found measurable effects on plasma lipids [7], though isolating astaxanthin’s individual contribution from multi-ingredient products is inherently difficult.
The 2025 meta-analysis (eight studies, 6 to 20 mg per day) found positive effects on HDL-C and triglycerides but no significant effect on LDL-C or total cholesterol [3]. A 2024 meta-analysis that compared several antioxidant lipid supplements against placebo, rather than pooling astaxanthin trials on their own, reported small favorable astaxanthin effects: LDL-C -0.11 mmol/L (95% CI -0.21 to -0.01), total cholesterol -0.22 mmol/L (-0.32 to -0.12), triglycerides -0.46 mmol/L (-0.83 to -0.10), and HDL-C +0.13 mmol/L (0.05 to 0.21) [15]. The LDL change is about 4 mg/dL on a US lipid panel. That result sits beside the 2020 pooled analysis finding no LDL, total cholesterol, or triglyceride effect [11], so different trial pools and inclusion rules give different answers. The 2024 authors say effects may depend on supplement type and cardiometabolic health status, and call for long-term trials [15].
In patients with myopathy, a group who often cannot tolerate statins, a combination of monacolin K (the active compound in red yeast rice) and astaxanthin helped maintain more favorable blood cholesterol levels compared to diet alone [8]. This points to a possible role for astaxanthin as a component of cholesterol management strategies in specific populations, even if the multi-ingredient design prevents attributing outcomes to astaxanthin alone.
Inflammation: A Core Link Between Astaxanthin and Cardiovascular Risk
Chronic low-grade inflammation is now recognized as a core mechanism in atherosclerotic cardiovascular disease, not merely a downstream consequence. Natural products with genuine anti-inflammatory activity are therefore of real interest in preventive cardiology [4]. Astaxanthin modulates several inflammation-relevant pathways, including suppression of pro-inflammatory cytokines and reduction in oxidative stress markers documented across both animal and early human research.
The 2026 rat study reported that astaxanthin and selenium co-supplementation reduced markers of systemic inflammation alongside lipid peroxidation findings [5]. This aligns with a coherent mechanistic picture: if astaxanthin reduces oxidative modification of LDL while simultaneously dampening inflammatory signaling in arterial walls, both pathways would be expected to contribute to lower atherosclerosis risk over time. Human trials measuring inflammatory biomarkers such as C-reactive protein with astaxanthin supplementation alone remain limited: a genuine evidence gap that future research needs to address.
One recent trial did test astaxanthin in people with chronic heart failure. In 80 patients given 20 mg per day or a maltodextrin placebo for 8 weeks, total antioxidant capacity (0.12 vs -0.04 mmol/L) and superoxide dismutase (156.92 vs 36.14 U/mL) rose more with astaxanthin, and malondialdehyde (-2.19 vs -0.68 nmol/L) and serum uric acid (-1.82 vs -0.63 mg/dl) fell more [16]. Those are oxidative stress markers, not cardiac outcomes. The improvements in dyspnea and fatigue were reported among astaxanthin-treated patients rather than as a comparison with placebo, and the dose was above the 4 to 12 mg range of most trials [16].
Endothelial Function: Protecting the Lining of Blood Vessels
The endothelium, the single-cell-thick layer lining blood vessels, regulates vascular tone, prevents abnormal clotting, and maintains arterial flexibility. Endothelial dysfunction is an early and potentially modifiable step in cardiovascular disease, occurring well before overt plaque formation. In a diabetic rat model, astaxanthin administration improved markers of endothelial dysfunction, suggesting it may help preserve vascular function under metabolic stress [9].
This is particularly relevant because people with diabetes carry substantially elevated cardiovascular risk, and endothelial dysfunction is a major contributing factor. The finding is from an animal model and cannot be directly applied to clinical practice, but it identifies a plausible mechanism through which astaxanthin might contribute to vascular health independent of its lipid-modifying effects. Controlled human studies examining endothelial function as a primary outcome with astaxanthin supplementation represent an important area for future investigation.
The human vascular trials so far are not encouraging. In the XANTHIN trial, 61 kidney transplant recipients took 12 mg of astaxanthin or placebo for a year, and there were no significant between-group differences in arterial stiffness (aortic pulse wave velocity), oxidative stress, or inflammation; the authors noted that larger-than-expected variability reduced the power of the study and raised the possibility of a type 2 error [17]. In 50 people with coronary artery disease taking 12 mg per day for 8 weeks, TNF-alpha and Sirtuin1 did not differ between the astaxanthin and placebo groups [18].
Astaxanthin and Blood Pressure: What Human Trials Show
Claims that astaxanthin lowers blood pressure are common, and they have a real origin. The proposed mechanism is that oxidative stress in the vessel wall reduces nitric oxide availability, so a membrane-based antioxidant could in principle support vasodilation. A 2017 cardiovascular review lists anti-hypertensive activity among astaxanthin’s reported effects, and the same review grades the underlying evidence as strong in vitro, moderate in animals and weak in humans [14]. Much of the animal work uses spontaneously hypertensive rats, a strain bred to develop high blood pressure, which is a uniform, genetically driven condition that differs from the heterogeneous hypertension seen in people.
The most useful human evidence is a 2020 systematic review and meta-analysis that pooled 14 randomized controlled trials. Astaxanthin consumption was not associated with systolic or diastolic blood pressure, fasting blood sugar, HbA1c, total cholesterol, LDL-C, triglycerides, BMI or body weight. It did find a small increase in HDL-C (weighted mean difference 1.473 mg/dL, 95% CI 0.319 to 2.627, p = 0.012), which is statistically real but small in clinical terms [11]. C-reactive protein fell only when astaxanthin was given for at least 12 weeks (weighted mean difference -0.528 mg/L, 95% CI -0.990 to -0.066) or at doses above 12 mg/day [11]. That is an inflammation marker, not a blood pressure result, and the two should not be read interchangeably.
An earlier meta-analysis of 7 randomized trials (10 treatment arms, 280 participants) looked at lipids and glucose rather than blood pressure. It found no significant effect on total cholesterol, LDL-C, HDL-C, triglycerides or glucose. For HDL-C the estimate was +1.75 mg/dL with a 95% CI of -0.92 to +4.42 (p = 0.199), and omitting any single study did not significantly change the estimates [12]. The two reviews point the same direction on HDL but disagree on whether it reaches significance, which is what a marginal effect typically looks like.
One trial measured blood pressure directly alongside metabolic markers. A 2023 triple-blind randomized trial gave 58 infertile women with polycystic ovary syndrome either placebo or astaxanthin at 2 x 6 mg/day for 8 weeks, with blood pressure assessed at the start and end. The reported significant changes were reductions in fasting blood sugar, HOMA-IR, fasting insulin, malondialdehyde, LDL-C and the total cholesterol to HDL-C ratio, and increases in total antioxidant capacity, HDL-C and QUICKI. Blood pressure is not among the outcomes listed as changing significantly. After adjusting for baseline age, BMI and biochemical values, QUICKI and fasting insulin lost significance while the other findings held [13].
A trial in 44 people with type 2 diabetes, who took 8 mg of astaxanthin or placebo daily for 8 weeks, did report a significant reduction in systolic blood pressure alongside higher adiponectin and lower visceral fat and triglycerides [19]. Blood pressure was not that trial’s headline outcome, and it is a single small study against a pooled null, so it adds a signal to test rather than a result to rely on.
Other pooled analyses lean the same way. A 2022 meta-analysis of seven double-blind trials found a modest effect on systolic pressure only when treatment lasted more than 8 weeks and no effect on diastolic pressure, and a pooled analysis of four trials in people with metabolic syndrome risk factors put the systolic change at borderline (p = 0.05, interval touching zero). Overall the blood pressure picture is null or borderline, not positive [22][21].
The honest reading is that anyone taking astaxanthin specifically to lower blood pressure is acting ahead of the evidence. This does not prove there is no effect, since no trial has been built around blood pressure as the primary outcome in people with hypertension. If blood pressure needs managing, use treatments with demonstrated effects and talk to your clinician before adding a supplement. See our side effects guide and drug interactions guide if you take antihypertensive medication.
Dosing, Food Sources, and Safety Considerations
Astaxanthin occurs naturally in salmon, shrimp, krill, and other marine organisms that feed on Haematococcus algae. Dietary intake from food is typically far lower than the doses used in trials. A study examining shrimp oil, which contains astaxanthin alongside other marine lipids, in children and adolescents found no significant effects on cardio-metabolic risk factors [10].
Supplement doses in human cardiovascular trials have generally ranged from 4 to 12 mg per day. US FDA GRAS notices for Haematococcus pluvialis extract cover small amounts added to foods per serving (0.1 and 0.15 mg of astaxanthin), not supplement doses, and are not FDA approval of supplements. The EU authorises astaxanthin food supplements at up to 8 mg/day, and EFSA has approved no health claims. Trials up to 12 mg/day for 12 weeks have not identified serious adverse effects [23][24][25][26]. Skin discoloration (carotenodermia) is well documented for excessive beta-carotene intake, but it has not been reported in published human astaxanthin studies. Evidence in pregnancy is insufficient, and supplementation during pregnancy or breastfeeding is not recommended.
🛒 Where to Buy Astaxanthin
- Nutrex Hawaii BioAstin Hawaiian Astaxanthin
softgels, 12 mg per softgel, 90 count: Hawaiian-grown Haematococcus pluvialis, sold as the High Potency 90-softgel bottle - Pure Synergy SuperPure Astaxanthin Extract
capsules, 60 count: Sold as an astaxanthin extract in a capsule rather than a softgel; the listing does not state a mg per capsule, so check the label for the dose before comparing it with the 12 mg bottles here - Naturalis New Zealand Astaxanthin
softgels, 12 mg per softgel, 120 count: New Zealand-grown rather than Hawaiian, and the largest bottle on this list at 120 softgels - NOW Foods Astaxanthin
softgels, 4 mg per softgel: The entry-level 4 mg dose, built on the Zanthin astaxanthin ingredient; a lower starting point than the 12 mg bottles above
As an Amazon Associate we earn from qualifying purchases. Astaxanthin products vary mainly by dose and by source, with 4mg and 12mg the common strengths and most of them derived from Haematococcus pluvialis algae, so check the label for the astaxanthin content per serving and prefer products that publish third-party testing.
A Note on the Evidence
The majority of mechanistic and high-dose evidence for astaxanthin’s cardiovascular effects comes from animal studies, and human trials are generally small, short-term, and often use astaxanthin in combination with other compounds; this article is informational context only and is not a basis for changing medications or cardiovascular treatment without consulting a qualified healthcare provider. Astaxanthin is not recommended during pregnancy or breastfeeding due to insufficient safety evidence in those populations.
Frequently Asked Questions
Does astaxanthin lower LDL cholesterol in humans?
Results in human trials are modest and mixed. Some studies show small LDL reductions, and a 2025 meta-analysis reviewed astaxanthin’s effects on LDL across multiple randomized controlled trials [3]. Animal research suggests it may lower LDL partly by reducing PCSK9 and upregulating LDL receptor expression [5], but these mechanisms have not been firmly confirmed in well-powered human studies.
Does astaxanthin raise HDL cholesterol?
A randomized controlled trial in adults with mild hyperlipidemia found that natural astaxanthin supplementation significantly increased serum HDL-cholesterol and the cardioprotective hormone adiponectin compared to placebo [2]. Pooled analyses are mixed: a 2020 meta-analysis found a small HDL increase of about 1.5 mg/dL, while a 2015 meta-analysis found no significant HDL effect [11][12], so replication in larger trials is needed before drawing firm conclusions.
Can astaxanthin help reduce cardiovascular inflammation?
Astaxanthin suppresses pro-inflammatory pathways including NF-κB signaling, which plays a central role in atherosclerosis [4]. Animal models demonstrate reductions in inflammatory biomarkers alongside improved lipid peroxidation markers [5]. Direct human trial data measuring cardiac-specific inflammatory biomarkers with astaxanthin supplementation alone is still limited, which is a recognized gap in the evidence.
Is astaxanthin safe for daily supplementation?
US FDA GRAS notices cover small amounts of astaxanthin added to foods, not supplement doses, and are not FDA approval of supplements. Trials at doses up to 12 mg/day for 12 weeks have not shown serious adverse effects [23][24]. Skin discoloration (carotenodermia) is well documented for very high beta-carotene intake, but it has not been reported in published human astaxanthin studies. Evidence during pregnancy is insufficient, so supplementation is not recommended for pregnant or breastfeeding individuals.
How does astaxanthin compare to other antioxidants for heart health?
Astaxanthin’s structural positioning across the full cell membrane bilayer, protecting both lipid and aqueous compartments, is considered a meaningful mechanical advantage over antioxidants confined to one phase [1]. Whether this translates into clinically superior outcomes compared to other antioxidants in cardiovascular disease has not been established in head-to-head human trials, so direct comparisons remain speculative.
Should astaxanthin be combined with other supplements for heart health?
Some research has examined combination approaches. Monacolin K combined with astaxanthin helped maintain favorable cholesterol levels in myopathy patients who could not tolerate statins [8], and selenium co-supplementation showed synergistic effects in animal research [5]. Combination strategies may be more effective than astaxanthin alone for some individuals, but any multi-supplement regimen should be discussed with a healthcare provider to assess appropriateness and potential interactions with medications.
Does astaxanthin lower blood pressure in humans?
Not according to the pooled human evidence. A 2020 meta-analysis of 14 randomized controlled trials found astaxanthin was not associated with systolic or diastolic blood pressure [11]. The belief that it lowers blood pressure rests largely on animal studies, and a cardiovascular review grades the evidence as strong in vitro, moderate in animals and weak in humans [14].
Can I take astaxanthin with blood pressure medication?
Discuss it with your prescriber first. The pooled trials did not show a blood pressure effect, so they offer no basis for expecting astaxanthin to add to or interfere with a medication, but interaction questions depend on your specific drugs. Our drug interactions guide covers what is known.
References
- Kidd P et al. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic (2011). PMID 22214255
- Yoshida H et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis (2010). PMID 19892350
- Fornari Laurindo L et al. Assessing the Effects of Moderate to High Dosage of Astaxanthin Supplementation on Lipid Profile Parameters-A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Pharmaceuticals (Basel, Switzerland) (2025). PMID 40872489
- Kulkarni A et al. Role of Anti-Inflammatory and Antioxidant Properties of Natural Products in Curing Cardiovascular Diseases. Current issues in molecular biology (2025). PMID 41296459
- Zaer HF et al. Selenium-Astaxanthin Co-Supplementation Synergistically Reduces PCSK9 Expression, Upregulates LDL Receptors, and Improves lipid profile and Cardiovascular Markers in Menopausal Ovariectomized Rats by attenuating inflammation and lipid peroxidation. Biological trace element research (2026). PMID 41984397
- Xu J et al. A combination of flaxseed oil and astaxanthin alleviates atherosclerosis risk factors in high fat diet fed rats. Lipids in health and disease (2014). PMID 24708887
- Pirro M et al. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. Pharmacological research (2016). PMID 27157250
- Villano I et al. The Role of Nutraceutical Supplements, Monacolin K and Astaxanthin, and Diet in Blood Cholesterol Homeostasis in Patients with Myopathy. Biomolecules (2022). PMID 36009012
- Zhao ZW et al. Ameliorative effect of astaxanthin on endothelial dysfunction in streptozotocin-induced diabetes in male rats. Arzneimittel-Forschung (2011). PMID 21650083
- Aref M et al. Effects of shrimp oil on cardio-metabolic risk factors in children and adolescents. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2023). PMID 35311593
- Xia W et al. The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials. Pharmacological research (2020). PMID 32755613
- Ursoniu S et al. Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. Archives of medical science : AMS (2015). PMID 25995739
- Jabarpour M et al. Astaxanthin supplementation impact on insulin resistance, lipid profile, blood pressure, and oxidative stress in polycystic ovary syndrome patients: A triple-blind randomized clinical trial. Phytotherapy research : PTR (2024). PMID 37874168
- Visioli F et al. Astaxanthin in cardiovascular health and disease: mechanisms of action, therapeutic merits, and knowledge gaps. Food & function (2017). PMID 27924978
- Wan S et al. Antioxidant Lipid Supplement on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis. Nutrients (2024). PMID 39064656
- Mohammadi SG et al. Impact of astaxanthin on oxidative markers, uric acid, and clinical symptoms in heart failure: a randomized clinical trial. BMC Cardiovascular Disorders (2025). PMID 41162864
- Coombes JS et al. Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial). American Journal of Clinical Nutrition (2016). PMID 26675778
- Heidari M et al. Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-alpha levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial. Frontiers in Nutrition (2023). PMID 37051124
- Mashhadi NS et al. Astaxanthin improves glucose metabolism and reduces blood pressure in patients with type 2 diabetes mellitus. Asia Pacific Journal of Clinical Nutrition (2018). PMID 29384321
- Kishimoto Y et al. Potential Anti-Atherosclerotic Properties of Astaxanthin. Marine drugs (2016). PMID 26861359
- Leung LY et al. Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis. Nutrients (2022). PMID 35631193
- Gao C et al. The Effects of Astaxanthin on Metabolic Syndrome: A Comprehensive Review. Marine drugs (2024). PMID 39852511
- US Food and Drug Administration GRN No. 294: Haematococcus pluvialis extract containing astaxanthin esters. US Food and Drug Administration (2010). source
- US Food and Drug Administration GRN No. 580: Haematococcus pluvialis extract containing astaxanthin esters. US Food and Drug Administration (2015). source
- European Food Safety Authority (EFSA NDA Panel) Safety of astaxanthin for its use as a novel food in food supplements. European Food Safety Authority (EFSA NDA Panel) (2020). source
- Nishida Y et al. Astaxanthin: Past, Present, and Future. Marine drugs (2023). PMID 37888449
- Tamami Iwamoto et al. Inhibition of Low-Density Lipoprotein Oxidation by Astaxanthin. Journal of Atherosclerosis and Thrombosis (2000). PMID 11521685
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
